Neoadjuvant Treatment in Breast Cancer; Relationship to HER2 status including HER2 Copy Number using Brightfield Dual in situ Hybridization

被引：0
|
作者：
Neville, Grace [1 ]
O'Connell, Fionnuala [1 ]
Bennett, Michael [1 ]
Feeley, Linda
O'Reilly, Seamus [1 ]
Browne, Tara Jane [1 ]
机构：
[1] Cork Univ Hosp, Cork, Ireland
来源：
MODERN PATHOLOGY | 2018年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
268
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [41] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
    Fehm, T.
    Lane, N.
    Solomayer, E.
    Wallwiener, D.
    Uhr, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
  • [42] Significance of HER2 Status in Neoadjuvant Chemotherapy for Breast Cancer Patients
    Wang, Chengqin
    Xing, Xiaoming
    Chen, Zhaoxu
    Wei, Zhimin
    Li, Yujun
    LABORATORY INVESTIGATION, 2023, 103 (03) : S226 - S228
  • [43] Impact of Chromosome 17 and HER2 Copy Number Variability on HER2 FISH in Breast Cancer Cases with CEP17 Copy Number Alterations
    Donaldson, Alana R.
    Shetty, Shashirekha
    Rivera, Christine
    Portier, Bryce P.
    Cook, James R.
    Budd, G. T.
    Downs-Kelly, Erinn
    Klein, Roger D.
    Lanigan, Christopher P.
    Tubbs, Raymond
    Calhoun, Benjamin C.
    LABORATORY INVESTIGATION, 2016, 96 : 40A - 41A
  • [44] Loss of HER2 after neoadjuvant treatment of HER2+early breast cancer
    Morales, S.
    Gasol Cudos, A.
    Rodriguez Galindo, A.
    Velasco, A.
    Canosa Morales, C.
    Sanchez Guzman, D. -R.
    Mele Olive, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S51 - S51
  • [45] Impact of Chromosome 17 and HER2 Copy Number Variability on HER2 FISH in Breast Cancer Cases with CEP17 Copy Number Alterations
    Donaldson, Alana R.
    Shetty, Shashirekha
    Rivera, Christine
    Portier, Boyce P.
    Cook, James R.
    Budd, G. T.
    Downs-Kelly, Erinn
    Klein, Roger D.
    Lanigan, Christopher P.
    Tubbs, Raymond
    Calhoun, Benjamin C.
    MODERN PATHOLOGY, 2016, 29 : 40A - 41A
  • [46] Dual HER2 blockade in adjuvant and neoadjuvant treatment of HER2-positive breast cancer: the role of pertuzumab
    Duchnowska, Renata
    ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (01): : 43 - 47
  • [47] Performance of chromogenic in situ hybridization on testing HER2 status in breast carcinoma
    Bchir, A.
    Abdessayed, N.
    Ben Abdelkhader, A.
    Mokni, M.
    HISTOPATHOLOGY, 2022, 81 : 32 - 32
  • [48] Dual HER2 Blockade in Neoadjuvant Treatment of HER2+Breast Cancer: A Meta-Analysis and Review
    Wang, Chaokun
    Chen, Jing
    Xu, Xiangyun
    Hu, Xiaochen
    Kong, Dejiu
    Liang, Gaofeng
    Wang, Xinshuai
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19
  • [49] Validation of Dual-Color Dual In Situ Hybridization for HER2/neu Gene in Breast Cancer
    Rathi, Aditi
    Sahay, Ayushi
    Shet, Tanuja M.
    Patil, Asawari
    Desai, Sangeeta B.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2024, 148 (04) : 453 - 460
  • [50] Assessment of HER2 status in breast cancer
    Penault-Llorca, F
    Cayre, A
    BULLETIN DU CANCER, 2004, 91 : S211 - S215
12345